Novel acyl carbamates and acyl / diacyl ureas show in vitro efficacy against Toxoplasma gondii and Cryptosporidium parvum

Abrahamsen, 2004, Complete genome sequence of apicomplexan, C. parvum. Science., 304, 441 Abubakar, 2007, Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis, Br. J. Clin. Pharmacol., 63, 387, 10.1111/j.1365-2125.2007.02873.x Alday, 2017, Drugs in development for toxoplasmosis: advances, challenges, and current status, Drug Des. Dev. Ther., 11, 273, 10.2147/DDDT.S60973 Araujo, 1991, Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii, Antimicrob. Agents Chemother., 35, 293, 10.1128/AAC.35.2.293 Arrowood, 1987, Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients, J. Parasitol., 73, 314, 10.2307/3282084 Boyom, 2014, Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica, Antimicrob. Agents Chemother., 58, 5848, 10.1128/AAC.02541-14 Centers for Disease Control and Prevention Cdc Centers for Disease Control and Prevention Cdc Chalmers, 2014, Cryptosporidium, 287 Checkley, 2015, A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium, Lancet Infect. Dis., 15, 85, 10.1016/S1473-3099(14)70772-8 Current, 1992, Techniques and laboratory maintenance of Cryptopsoridium, p 44-77, 44 Deng, 2020, Synthesis, in vitro and in vivo biological evaluation of dihydroartemisinin derivatives with potential anti-Toxoplasma gondii agents, Bioorg. Chem., 94, 103467, 10.1016/j.bioorg.2019.103467 Downey, 2008, Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model, Antimicrob. Agents Chemother., 52, 3106, 10.1128/AAC.00207-08 Fomovska, 2012, Unique parasite secretory pathway disrupted by novel hydroxybenzamides,, Antimicrob. Agents Chemother., 56, 2666, 10.1128/AAC.06450-11 Furtado, 2011, Toxoplasmosis: a global threat, J. Global Infect. Dis., 3, 281, 10.4103/0974-777X.83536 Garcia Hernandez, 2017, Convenient one-pot two-step synthesis of symmetrical and unsymmetrical diacyl ureas, acyl urea/carbamate/thiocarbamate derivatives, and related compounds, Synthesis, 49, 2163, 10.1055/s-0036-1588724 Gargala, 2000, Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells, J. Antimicrob. Chemother., 46, 57, 10.1093/jac/46.1.57 Grzegorzewicz, 2012, Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane, Nat. Chem. Biol., 8, 334, 10.1038/nchembio.794 Gubbels, 2003, High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein, Antimicrob. Agents Chemother., 47, 309, 10.1128/AAC.47.1.309-316.2003 Guo, 2019, Synthesis and biological evaluation of (+)-Usnic acid derivatives as potential anti-Toxoplasma gondii agents, J. Agric. Food Chem., 67, 9630, 10.1021/acs.jafc.9b02173 Kochanowsky, 2018, Toxoplasma gondii, Curr. Biol., 28, R770, 10.1016/j.cub.2018.05.035 Krivogorsky, 2013, Tryptanthrin derivatives as Toxoplasma gondii inhibitors – structure-activity-relationship of the 6-position, Bioorg. Med. Chem. Lett, 23, 1032, 10.1016/j.bmcl.2012.12.024 Kuhlenschmidt, 2016, Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) in vitro by pyrazolopyrimidine derivatives does not correlate with sensitivity of Cryptosporidium parvum growth in cell culture, Antimicrob. Agents Chemother., 60, 570, 10.1128/AAC.01915-15 Li, 2019, Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum, PLoS Pathog., 15, 10.1371/journal.ppat.1007953 Luan, 2019, Synthesis and biological evaluation of ursolic acid derivatives bearing triazole moieties as potential anti-Toxoplasma gondii agents, J. Enzym. Inhib. Med. Chem., 344, 761, 10.1080/14756366.2019.1584622 Martins-Duarte, 2009, Thiolactomycin analogues as potential anti-Toxoplasma gondii agents, Parasitol. Int., 58, 411, 10.1016/j.parint.2009.08.004 Mboera, 2019, Mortality patterns of toxoplasmosis and its comorbidities in Tanzania: a 10-year retrospective hospital-based survey, Front. Public Health, 7, 25, 10.3389/fpubh.2019.00025 McLeod, 2006, Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis, Pediatr. Infect. Dis. J., 25, 270, 10.1097/01.inf.0000202070.59190.9a Montazeri, 2015, Effect of propranolol alone and in combination with pyrimethamine on acute murine toxoplasmosis, Jundishapur J. Microbiol., 8, 10.5812/jjm.22572 Protopopova, 2005, Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines, J. Antimicrob. Chemother., 56, 968, 10.1093/jac/dki319 Rajapakse, 2013, Antibiotics for human toxoplasmosis: asystematic review of randomized trials, Pathog. Glob. Health, 107, 162, 10.1179/2047773213Y.0000000094 Witola, 2017, Targeted gene knockdown validates the essential role of lactate dehydrogenase in Cryptosporidium parvum, Int. J. Parasitol., 47, 867, 10.1016/j.ijpara.2017.05.002 Zhang, 2018, Synthesis and evaluation of novel arctigenin derivatives as potential anti-Toxoplasma gondii agents, Eur. J. Med. Chem., 158, 414, 10.1016/j.ejmech.2018.08.087 Zhou, 2014, Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo, Antimicrob. Agents Chemother., 58, 1789, 10.1128/AAC.02225-13